NCT05395052 2023-09-21FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated5 enrolled
NCT02627274 2022-11-22A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)Hoffmann-La RochePhase 1 Completed134 enrolled
NCT00004163 2017-04-18Trastuzumab in Treating Patients With Advanced Salivary Gland CancerDana-Farber Cancer InstitutePhase 2 Completed14 enrolled